Setup

GN Audio (GNNDY) is a Danish enterprise headset and gaming audio company executing a strategic split: selling its Hearing segment to Amplifon for DKK 3.5–4.5B and retaining Enterprise + Gaming as the continuing business. The capital return narrative — 25–32% of market cap returned post-close — has dominated the stock's framing. Logitech's FY2026 10-K (filed 2026-05-21) provides the cross-ticker evidence that settles the key disputed question underneath it.

What the Filing Says

Logitech FY2026 EMEA: $1,539.1M, +8.9% reported / +3% constant currency. Video Collaboration +10%. Keyboards +6%. Pointing Devices +9%. Headsets: $179.8M, flat — 0% growth.

Two things follow directly from the primary source.

The macro defense is closed. GN management attributed three consecutive quarters of double-digit EMEA Enterprise decline to "a more challenging macro environment in Europe." Logitech just printed a 9% beat against its own "low single-digit" EMEA guide. The EMEA enterprise technology peripheral market is not contracting. GN's decline is company-specific.

LOGI is not the headset share gainer. LOGI EMEA growth was VC-camera driven, not headset. The sub-$79 Teams-certified headset tier — where GN is losing volume — went to Chinese OEMs. Two independent management teams confirm the mechanism: GN's CEO explicitly admitted "we have lost entry-level market share to Chinese OEMs" on the Q4 2025 call. LOGI's flat headset line confirms they aren't taking it.

The rotation is structural. Chinese OEM Teams certification requires 12+ months of distribution-channel embedding. Reversing it requires product differentiation at price parity, not macro normalization.

What the Market Thinks

Solving for the bull probability implied by $43.96 against the scenario set:

Market-implied recovery probability: 81.1%. The current price requires an 81% chance Evolve3's mid/entry tier launches successfully and arrests the EMEA slide. We have it at 40%.

The 40% reflects genuine product cycle optionality — Evolve3 is a real product, the premium tier launched in Q1 2026, mid/entry follows in Q3/Q4. But once Chinese OEM Teams certification embeds (12+ months of distribution channel), reversing it requires both price parity and a demonstrated quality differential. That combination is what Evolve3 mid/entry must deliver against an OEM tier already anchored at $49–79. Historical headset market recoveries against established Chinese OEM distribution are poor. We do not have it below 30%.

E[intrinsic] = $31.6/ADR. E[return] = −28.2%. Forward idio Sharpe = −0.57 (marginally investable; half-Kelly minimum applies).

The gap is 41 percentage points on a single binary: does Evolve3 work?

Why the Gap Exists

The edge claim is specific: no US sell-side research has synthesized the LOGI EMEA cohort data with the GN Enterprise decline. The cross-ticker read-through exists in primary sources — two filings and two earnings calls — but has not been published as a bear case. The counterparty is an analyst community anchored on the capital return, not the continuing business.

The other three reasons the market embeds 81% recovery:

• Capital return dominates framing. DKK 3.5–4.5B is explicit management commitment. Analysts anchor on the return, not what the remaining business looks like post-close.
• CEO language taken at face value. "We will regain this share" is a strong statement. Without the cohort cross-check, there is no primary-source contradiction.
• P/E optics. Forward 11.33x screens cheap — until you adjust for continuing-ops margins at 8–9% EBITA with revenue in decline.

Risks

1. Momentum crash — the largest near-term risk. MTUM β = −1.249 (t = −2.05, statistically significant). GNNDY is a momentum loser: RSI 39, below both moving averages, −4.4% one-month. A momentum reversal (MTUM +20%) produces a GNNDY +25% move with zero fundamental change. The bear's worst scenario is being right on the idio thesis and losing on the factor.

2. Capital return execution. 82% probability the Hearing deal closes by end-2026. If it does, the stock pops 25–32% regardless of Enterprise trajectory. The bear thesis resolves before the capital return close — timing matters.

3. Evolve3 success (40% P). Mid/entry tier launch in Q3/Q4 2026 at competitive pricing arrests the share loss. This is a genuine probability, not a tail. Pricing vs the Chinese OEM $49–79 tier remains unknown until launch .

4. Market beta amplification. SPY β = 2.43. A 10% macro rally generates a 24% paper loss against the idio short thesis before fundamentals play out.

Catalysts

Critical timing conflict: The bear window lives between Q2 confirmation (August) and Hearing close (November–December) — approximately 3–4 months. A short entered at the wrong side of this window captures the downside and then gives it back on the capital return pop.

What Would Change Our Mind

• Evolve3 mid/entry SKUs priced at $59–79 with channel-confirmed EMEA sell-through by Q4 2026
• GN Q2 Enterprise EMEA declining less than 5%, or turning positive
• Chinese OEM Teams certification revoked, supply disrupted, or distribution contracts lost
• Hearing deal fails or is renegotiated materially lower — removes the capital return floor and changes the whole setup

Evidence